NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
(Total Views: 241)
Posted On: 12/10/2021 3:12:07 PM
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular Diagnostics, a peer-reviewed international medical journal that has an impact factor of 5.2. “We are very pleased with the publication of our technical paper on CDA cancer detection technology by a peer-reviewed international journal in the field of medicine,” said Dr. Chris Yu, AnPac Bio’s chairman and CEO. “The review and subsequent acceptance of our paper based on the novel and original biophysics-based CDA cancer detection technology for publication is very gratifying and indicates what we believe is a positive level of recognition for this approach. The findings reported in this study validates the CDA technology and has laid both the conceptual and practical groundwork for CDA technology to be used in large population cancer screening. We will continue to invest in research and development and, at the same time, speed up our commercialization process.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular Diagnostics, a peer-reviewed international medical journal that has an impact factor of 5.2. “We are very pleased with the publication of our technical paper on CDA cancer detection technology by a peer-reviewed international journal in the field of medicine,” said Dr. Chris Yu, AnPac Bio’s chairman and CEO. “The review and subsequent acceptance of our paper based on the novel and original biophysics-based CDA cancer detection technology for publication is very gratifying and indicates what we believe is a positive level of recognition for this approach. The findings reported in this study validates the CDA technology and has laid both the conceptual and practical groundwork for CDA technology to be used in large population cancer screening. We will continue to invest in research and development and, at the same time, speed up our commercialization process.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)AnPac Bio-Medical Science Co. Ltd. (ANPC) Stock Research Links
Scroll down for more posts ▼